Evidence map›Paper›PMID 34955687›Full record

ArticlePathology oncology research : POR2021

Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With Anlotinib.

Fangling Hu, Liang Guo, Jieqing Yu, Daofeng Dai, Yuanping Xiong, Yuanqiao He, Wensheng Zhou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Establishment and characterization of a testicular yolk sac tumor PDX model.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Fangling HuDepartment of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Nangchang University, Nanchang, China.
Liang GuoDepartment of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Nangchang University, Nanchang, China.
Jieqing YuJiangxi Institute of Otorhinolaryngology-Head and Neck Surgery, Nanchang, China.
Daofeng DaiDepartment of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Nangchang University, Nanchang, China.
Yuanping XiongDepartment of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Nangchang University, Nanchang, China.
Yuanqiao HeLaboratory Animal Science Center of Nanchang University, Nanchang, China.
Wensheng ZhouDepartment of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Nangchang University, Nanchang, China.
Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntineoplastic AgentsApoptosisBiomarkers, TumorCell ProliferationHead and Neck NeoplasmsHumansIndolesMiceQuinolinesSquamous Cell Carcinoma of Head and NeckTumor BurdenXenograft Model Antitumor AssaysanlotinibAntineoplastic AgentsBiomarkers, TumorIndolesQuinolinesanlotinibdrug sensitivityhead-and-neck squamous cell carcinomapatient-derived xenografttumor inhibition

Identifiers

PMID34955687
PMCPMC8696349
OpenAlexW4200007006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.